Major Study Finds Cannabis Ineffective for Anxiety, Depression, and PTSD

A comprehensive analysis published in The Lancet reveals that medicinal cannabis provides no effective treatment for anxiety, depression, or PTSD, despite widespread use for these conditions. This matters because roughly 27% of adults in North America use cannabis medically, with half seeking mental health benefits from a substance that may actually harm them.

The University of Sydney-led research represents the largest safety and effectiveness review of cannabinoids for mental health conditions to date. Researchers found that cannabis use could worsen mental health outcomes by increasing psychosis risk, promoting addiction, and delaying access to proven treatments. For substance use disorders, results were mixed—cannabis showed potential for treating cannabis dependency when combined with therapy, but increased cravings in people with cocaine-use disorder.

Limited evidence suggested possible benefits for autism, insomnia, tics, and Tourette's syndrome, though researchers emphasized the supporting data was weak. The study confirmed established benefits for epilepsy-related seizures, multiple sclerosis spasticity, and certain pain types, but mental health applications fell short of clinical standards.

For health-conscious individuals, these findings suggest avoiding cannabis for mental health self-treatment and instead pursuing evidence-based therapies. The research highlights a concerning gap between popular perception and scientific evidence, particularly as cannabis accessibility increases globally. Healthcare providers should exercise caution when considering cannabis recommendations for mental health conditions, given the potential for harm and lack of therapeutic benefit.